Medicine

North America Liquid Biopsy Market Report 2020 Featuring Major Players - Exosome Diagnostics, Thermo Fisher Scientific and Bio-Rad Laboratories

Friday, September 18, 2020 - 5:00pm

North America, the liquid biopsy market, is anticipated to reach US$ 3,531.44 Mn in 2027 from US$ 1,651.23 Mn in 2019.

Key Points: 
  • North America, the liquid biopsy market, is anticipated to reach US$ 3,531.44 Mn in 2027 from US$ 1,651.23 Mn in 2019.
  • The liquid biopsy market is growing primarily due to the increasing prevalence of cancer.
  • On the other hand, increasing liquid biopsy due to growing application and advancements is expected to have a positive impact on the growth of the North American liquid biopsy market in the coming years.
  • Exosome Diagnostics Inc., Thermo Fisher Scientific Inc. and Bio-Rad Laboratories Inc. are among the major companies manufacturing liquid biopsy testing products to detect cancer.

Musculoskeletal Disorders Pipeline Database 2020: Osteoarthritis, Osteoporosis, Rheumatoid Arthritis, Systemic lupus erythematosus, and Ankylosing Spondylitis - ResearchAndMarkets.com

Friday, September 18, 2020 - 4:34pm

Musculoskeletal Disorders Pipeline Highlights Database - 2020, provides the most up-to-date information on key pipeline products in the global Musculoskeletal Disorders market.

Key Points: 
  • Musculoskeletal Disorders Pipeline Highlights Database - 2020, provides the most up-to-date information on key pipeline products in the global Musculoskeletal Disorders market.
  • It covers emerging therapies for Musculoskeletal Disorders in active clinical development stages including early and late stage clinical trials.
  • Key indications covered in this database include Osteoarthritis, Osteoporosis, Rheumatoid Arthritis, Systemic lupus erythematosus, and Ankylosing Spondylitis.
  • Key indications covered in this database include Osteoarthritis, Osteoporosis, Rheumatoid Arthritis, Systemic lupus erythematosus, and Ankylosing Spondylitis.

United States Rheumatoid Arthritis Market and Competitive Landscape Report 2020: Epidemiology, Key Products Marketed, Market Valuations and Forecast, Drugs Sales and Market Shares 2016-2025 - ResearchAndMarkets.com

Friday, September 18, 2020 - 4:09pm

US Rheumatoid Arthritis Market and Competitive Landscape Highlights - 2020, provides comprehensive insights into Rheumatoid Arthritis pipeline products, Rheumatoid Arthritis epidemiology, Rheumatoid Arthritis market valuations and forecast, Rheumatoid Arthritis drugs sales and competitive landscape in the US.

Key Points: 
  • US Rheumatoid Arthritis Market and Competitive Landscape Highlights - 2020, provides comprehensive insights into Rheumatoid Arthritis pipeline products, Rheumatoid Arthritis epidemiology, Rheumatoid Arthritis market valuations and forecast, Rheumatoid Arthritis drugs sales and competitive landscape in the US.
  • The research is classified into seven sections - Rheumatoid Arthritis treatment options, pipeline products, market analysis comprising of epidemiology, key products marketed, market valuations and forecast, drugs sales and market shares.
  • Rheumatoid Arthritis pipeline: Find out the products in clinical trials for the treatment of Rheumatoid Arthritis by development phase 3, phase 2, and phase 1, by pharmacological class and companies developing the products
    Rheumatoid Arthritis drugs: Identify key products marketed and prescribed for Rheumatoid Arthritis in the US, including trade name, molecule name, and company
    Rheumatoid Arthritis market valuations: Find out the market size for Rheumatoid Arthritis drugs in 2019 in the US.
  • Find out how the market advanced from 2016 and forecast to 2025
    Rheumatoid Arthritis drugs market share: Find out the market shares for key Rheumatoid Arthritis drugs in the US
    Evaluate commercial market opportunity assessment, positioning, and segmentation for Rheumatoid Arthritis products

Japan Cancer Oncology Drug Therapeutics Market Sales Size Offers US$ 15 Billion Opportunity With 1600 Drug In Clinical Trials

Friday, September 18, 2020 - 3:57pm

NEW DELHI, Sept. 18, 2020 /PRNewswire/ -- "Japan Cancer Drug Market, Dosage, Price & Clinical Trials Insight 2025" Report Highlights:

Key Points: 
  • NEW DELHI, Sept. 18, 2020 /PRNewswire/ -- "Japan Cancer Drug Market, Dosage, Price & Clinical Trials Insight 2025" Report Highlights:
    Japan Cancer Drug Market Opportunity: > US$ 15 Billion by 2025
    Insight on Cancer Drugs In Clinical Trials: 360 Drugs
    Ongoing Clinical Trials for Cancer Drugs: 1600 Trials
    Marketed Cancer Drug Clinical Insight by Companies & Indication: 141 Drugs
    Cancer Clinical Pipeline By Company, Indication & Phase
    Japan in the past few years have been observing influx in the record of novel oncology drugs that have been approved and getting used to treat millions of patients that are suffering from any type of cancer.
  • As per the report findings for Japan Cancer Drug Market, spending of the revenue in Japan is mostly concentrated towards the cancer types that have been prevailing badly in the country.
  • All this is estimated to impact the cancer drug market and the costs of the drug in Japan over the next decade.
  • Overall, the cancer drug market in Japan is estimated to reach numerous billion dollars in the coming years, leveraging the country to be the most dominant cancer drug market in Asia.

Japan Cancer Oncology Drug Therapeutics Market Sales Size Offers US$ 15 Billion Opportunity With 1600 Drug In Clinical Trials

Friday, September 18, 2020 - 3:59pm

NEW DELHI, Sept. 18, 2020 /PRNewswire/ -- "Japan Cancer Drug Market, Dosage, Price & Clinical Trials Insight 2025" Report Highlights:

Key Points: 
  • NEW DELHI, Sept. 18, 2020 /PRNewswire/ -- "Japan Cancer Drug Market, Dosage, Price & Clinical Trials Insight 2025" Report Highlights:
    Japan Cancer Drug Market Opportunity: > US$ 15 Billion by 2025
    Insight on Cancer Drugs In Clinical Trials: 360 Drugs
    Ongoing Clinical Trials for Cancer Drugs: 1600 Trials
    Marketed Cancer Drug Clinical Insight by Companies & Indication: 141 Drugs
    Cancer Clinical Pipeline By Company, Indication & Phase
    Japan in the past few years have been observing influx in the record of novel oncology drugs that have been approved and getting used to treat millions of patients that are suffering from any type of cancer.
  • As per the report findings for Japan Cancer Drug Market, spending of the revenue in Japan is mostly concentrated towards the cancer types that have been prevailing badly in the country.
  • All this is estimated to impact the cancer drug market and the costs of the drug in Japan over the next decade.
  • Overall, the cancer drug market in Japan is estimated to reach numerous billion dollars in the coming years, leveraging the country to be the most dominant cancer drug market in Asia.

AIkido Pharma Announces Update On Its Use Of Artificial Intelligence

Friday, September 18, 2020 - 3:00pm

The development of products and tools to provide extensive information on PDA markers to guide personalized medicine.

Key Points: 
  • The development of products and tools to provide extensive information on PDA markers to guide personalized medicine.
  • The assembly of survival associations of individual markers from ONCOLNC.org into sets that will help identify novel targets in PDA.
  • Information about gene and protein function in human PDA patients and human PDA cancer cell lines to help prioritize individual diagnostic markers.
  • AIkido was initially formed in 1967 and is a biotechnology company with a diverse portfolio of small-molecule anti-cancer therapeutics.

United States $3.9 Billion Radiation Oncology Markets: Analysis 2016-2019 & Forecasts 2020-2027

Friday, September 18, 2020 - 3:00pm

The U.S. radiation oncology market size is expected to reach USD 3.9 billion by 2027, expanding at a CAGR of 5.0%.

Key Points: 
  • The U.S. radiation oncology market size is expected to reach USD 3.9 billion by 2027, expanding at a CAGR of 5.0%.
  • In application, internal beam radiation therapy is estimated to witness the fastest growth rate during the forecast period owing to the cost-effectiveness and accuracy of brachytherapy.
  • Increasing the prevalence of cancer and technological advancements in radiation oncology are some of the key factors responsible for market growth.
  • Advancements in radiation oncology can enable the delivery of a high dose to a target area without any damage to adjacent healthy tissues.

National Kidney Foundation and Transplant Genomics Lace-Up for Kidney Patients

Friday, September 18, 2020 - 2:04pm

To help keep kidney patients, and those who care for them, safe during the national pandemic, this year's Kidney Walk has transitioned to a new, virtual format.

Key Points: 
  • To help keep kidney patients, and those who care for them, safe during the national pandemic, this year's Kidney Walk has transitioned to a new, virtual format.
  • "As a transplant patient, I can tell you organ rejection is a patient's greatest fear," said Kevin Longino, CEO and kidney transplant patient. "
  • COVID-19 has been particularly devastating to kidney transplant patients and support for our community is needed now more than ever before.
  • We're grateful to Transplant Genomics for their sponsorship of our Kidney Walk and for helping us continue with our mission to improve the lives of kidney patients nationwide."

CEL-SCI Awarded European Patent for LEAPS Vaccine in Treatment of Rheumatoid Arthritis

Friday, September 18, 2020 - 2:00pm

CEL-SCI Corporation (NYSE American: CVM) today announced that the European Patent Office has issued CEL-SCI patent: European Patent 2989121 to be published on October 7, 2020, and titled Method of Preparation and Composition of Peptide Constructs for Treatment of Rheumatoid Arthritis for the Companys LEAPS platform technology.

Key Points: 
  • CEL-SCI Corporation (NYSE American: CVM) today announced that the European Patent Office has issued CEL-SCI patent: European Patent 2989121 to be published on October 7, 2020, and titled Method of Preparation and Composition of Peptide Constructs for Treatment of Rheumatoid Arthritis for the Companys LEAPS platform technology.
  • CEL-SCIs LEAPS technology relates to peptide constructs which may be useful in the treatment or prevention of autoimmune diseases, particularly rheumatoid arthritis, asthma, allergies, and host versus graft (or graft versus host) rejection.
  • LEAPS is also currently being tested at the University of Georgia vaccine center against COVID-19, said Dr. Daniel Zimmerman, Senior Vice President of Research, Cellular Immunology.
  • The Companys LEAPS technology is being developed for rheumatoid arthritis and as a potential treatment of COVID-19 in hospitalized and at-high-risk patients.

Natera to Present New Gastrointestinal Cancer Data at the ESMO Annual Meeting

Friday, September 18, 2020 - 2:03pm

Natera will present four abstracts one oral and three poster presentations which highlight applications for detecting MRD levels and tracking tumor clonal evolution in CRC and in esophageal adenocarcinoma.

Key Points: 
  • Natera will present four abstracts one oral and three poster presentations which highlight applications for detecting MRD levels and tracking tumor clonal evolution in CRC and in esophageal adenocarcinoma.
  • "We're delighted to share new data at this year's ESMO meeting, which shows the broad potential of our tumor-informed approach to MRD assessment," said Alexey Aleshin, M.D., M.B.A., Senior Medical Director of Oncology at Natera.
  • "These studies demonstrate that Signatera provides clinically actionable information that can improve the management of patients with multiple different solid cancers."
  • Signatera test performance has been clinically validated in multiple cancer types including colorectal, non-small cell lung, breast, and bladder cancers.